. Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease. J Clin Pharmacol. 2015 Feb;55(2):221-9. Epub 2014 Sep 16 PubMed.


Please login to recommend the paper.


No Available Comments

Make a Comment

To make a comment you must login or register.